3 March 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Azacitidine (Vidaza) - new indication
  
• Eribulin mesylate (Halaven) - new indication
  
• Alirocumab (Praluent) - new medicine
  
• Netupitant with palonosetron hydrochloride (Akynzeo) - new combination product
  
• Aprepitant (Emend) - new indication
  
• Brentuximab vedotin (Adcetris) - new indication
  
• Nivolumab (Opdivo) - new indication
  
• Reslizumab (Cinqaero) - new medicine
  

Read TC agenda [French]